Back to All Events

4th Annual Innovative Approaches to Brain Tumor Management

February 1, 2019

Seattle Science Foundation
550 17th Avenue, James Tower, Suite 600
Seattle, WA 98122

Innovative Approaches to Brain Tumor Management is targeted towards healthcare providers who manage and treat patients with brain tumors. Leading experts in the field will come together to discuss the future of brain tumor management including the progress in personalized medicine and implications of immunotherapy in specializing treatment. This course is designed to focus on the future of brain tumor therapy with the goal of improving treatment response rates, outcomes, and overall patient care.

Registration Form

Unable to view registration form below?  Click here.

powered by Typeform


7:30 a.m.
Breakfast & Registration

8 a.m.
Welcome & Announcements

Charles Cobbs, M.D. & Zachary N. Litvack, M.D.

8:15 a.m.
Novel Genetics and Diagnostic Criteria – Multiforme No More
Meghan Driscoll, M.D.

9 a.m.
An Anatomic Transcriptional Atlas of Human Glioblastoma (GBM) and Trials for GBM Stem Cells
Parvinder Hothi, Ph.D.

9:40 a.m.
The Role of Cytomegalovirus in Tumorigenesis – Potential Treatment Target? 

Charles Cobbs, M.D.

10:20 a.m.
Break & Exhibits

10:35 a.m.
Keynote: The Potential of Oncolytic Virotherapy for Glioma
(via broadcast)
James Markert, M.D., M.P.H., Honored Speaker

11:15 a.m.
BRCAness in Malignant Gliomas:  Missing the IDH1 Story
John M. Henson, M.D, M.B.A.

11:55 a.m.
Exhibits & Break to pick up Lunch

12:10 p.m.
Immunotherapy for Brain Cancer (Working Lunch - Unaccredited)
Marnix L. Bosch, Ph.D., MBA

12:50 p.m.
Advances in Image-Guided Resection

Sunit Das, M.D., Ph.D., M.A.

1:30 p.m.
Single Port Craniotomy for Resection of Deep Cerebral Glioma and Metastases
Zachary N. Litvack, M.D.

2:10 p.m.
Point-of-Care Raman Spectroscopy
Daniel A. Orringer, M.D.

2:50 p.m.
Neurophysiologic-Guided Resection of Insular Glioma
Nader Sanai, M.D.

3:30 p.m.
Advances in Fluorescence-Guided Resection of Glioma (Fluorescein vs. ALA)

Shawn Hervey-Jumper, M.D.

4:10 p.m.
Augmented Reality-Guided Resection of Brain Tumors 
Robert G. Louis, M.D.

4:50 p.m.


Charles Cobbs, M.D.
Course Co-Chair
Director, Ben & Catherine Ivy Center
for Advanced Brain Tumor Treatment
Swedish Neuroscience Institute
Seattle, Washington

Sunit Das, M.D., Ph.D., M.A.
Associate Professor of Surgery
University of Toronto
Toronto, Ontario

Meghan Driscoll, M.D.
Seattle, Washington

Shawn Hervey-Jumper, M.D.
Assistant Professor in Residence
Neurological Surgery
University of California San Francisco
San Francisco, California

John M. Henson, M.D., M.B.A.
Ben & Catherine Ivy Center
for Advanced Brain Tumor Treatment
Seattle, Washington

Parvinder Hothi, Ph.D.
Senior Scientist
Ben & Catherine Ivy Center
for Advanced Brain Tumor Treatment
Swedish Neuroscience Institute
Seattle, Washington

Keynote Speaker
James Markert, Jr., M.D., M.P.H.
James Garber Galbraith Endowed Chair of Neurosurgery
University of Alabama at Birmingham
Birmingham, Alabama

Zachary N. Litvack, M.D., FAANS, FACS
Course Co-Chair

Director, Skull Base & Minimally Invasive Neurosurgery
Swedish Neuroscience Institute
Seattle, Washington

Robert G. Louis, M.D.
Program Advisor of the Skull Base and 
Pituitary Tumor Program
Hoag Hospital Orange County
Newport Beach, California

Needs Statement

A paradigm shift has occurred in the evolution of how we treat patients with brain tumors. In recent years, researchers have found some changes in genes, chromosomes, and proteins inside brain tumor cells that can be used to help predict a patient’s prognosis, or help guide treatment. Recent advances in imaging, surgical approaches, and laser therapy have made surgery for brain tumors much safer and more successful. And, in 2016, the World Health Organization issued a major restructuring of how tumors of the central nervous system are defined. 

Despite the advances in brain tumor diagnosis, treatment and management, there is a formidable quality gap in the lack of dissemination, comprehension, and application of the latest evidence and practice recommendations.  The U.S. Institute of Medicine reports that scientific knowledge about best care is not applied systematically or expeditiously to clinical practice. It takes an average of 17 years for new knowledge generated by randomized controlled trials to be incorporated into practice, and then the application is highly uneven.

Following guidelines should be of primary importance; failure in guidelines implementation has a strong influence on appropriateness of care, clinical efficiency, healthcare costs and patients’ quality of life. Surveys of clinicians have shown that a major barrier to using current research evidence is the lack of awareness of new guidelines and the time, effort and skills needed to access the right information among the massive volumes of research.


By attending this course, the participant will provide better patient care through an increased ability to: 

  • Recognize the role that gene mutation (loss of function, gain of function, amplification) and promoter regulation play in the clinical and histologic behavior of primary brain tumors.

  • Outline the role that viral infection and viral DNA play in tumorigenesis.

  • Identify potential uses for tumor stem cell screening in devising personalized treatment plans.

  • Understand the roles that both ionizing and non-ionizing radiation have on treatment of human glioblastoma and other tumors.

  • Recognize the impact advanced MR, in-vivo fluorescence and in-vivo spectrographic imaging techniques have on progression free and overall survival.

  • Identify patients who may benefit from advanced mapping, augmented reality and minimally invasive surgical techniques over more traditional surgical approaches.

Intended Audience

This course is intended for neurosurgeons, neuro-oncologists, medical oncologists, neuroradiologists, radiation therapists, and allied health professionals who specialize in the treatment of patients with brain tumors in Washington, Alaska, Montana, Oregon, and Idaho.

CME Information

Accreditation with Commendation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Swedish Medical Center and the Seattle Science Foundation. Swedish Medical Center is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™

Swedish Medical Center designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This symposium is financially supported in part by educational grants in accordance with ACCME’s Standards for Commercial Support.  At the time of this printing, a complete listing of commercial supporters was not available.  Appropriate acknowledgment will be given to all supporters at the time of the symposium. 


The Seattle Science Foundation is located at 550 17th Avenue, James Tower, Suite 600 in Seattle, Washington. Parking is available in the garage on 16th Avenue between Cherry and Jefferson at a maximum fee of $16.50.  From I-5 (northbound and southbound), take the James Street exit.  Travel east on James Street.  James will become Cherry Street.  Turn right (south) on 16th Avenue.  Turn right into the main garage entrance.

For Further Information

Phone: (206) 732-6500
Fax: (206) 732-6599

Related Events

Earlier Event: January 24
Neurology Grand Rounds 2019
Later Event: February 6
Spine Case Conference Series 2019